help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Geller, J.
Right arrow Articles by Nachtsheim, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Geller, J.
Right arrow Articles by Nachtsheim, D. A.

Journal of Clinical Endocrinology & Metabolism, Vol 58, 36-40, Copyright © 1984 by Endocrine Society

ARTICLES

Tissue dihydrotestosterone levels and clinical response to hormonal therapy in patients with advanced prostate cancer

J Geller, DJ de la Vega, JD Albert and DA Nachtsheim

Dihydrotestosterone (DHT) levels were measured by RIA in tumor tissue from 32 men with advanced prostate cancer and correlated with their clinical responses to antiandrogen therapy. In 24 patients with tumor tissue DHT levels greater than 2.5 ng/g, 20 initially responded to therapy with partial objective regression or were objectively stable for 12 or more months, while 4 patients relapsed in less than 1 yr. The average disease-free interval in this group was 24 months, with 9 patients still continuing in partial objective regression or objective stability. Of 8 patients with DHT levels less than 2.0 ng/g, 5 had either objective progression or were objectively stable for 6 months or less; 2 other patients have completed remissions ranging from 16-24 months, while 1 patient remains objectively stable for 21 months to date. The average disease-free interval in patients with DHT levels less than 2.0 ng/g was 9.75 months, which is significantly less (P less than 0.001) than that of patients with DHT levels greater than 2.5 ng/g. There was no discernible relationship between the Gleason histological grade of prostate cancer and initial clinical response to therapy in these same patients. In summary, this study supports the thesis that tissue DHT levels may be a useful marker for predicting the clinical response of prostate cancer to antiandrogen therapy.


This article has been cited by other articles:


Home page
 Endocr Relat CancerHome page
H. I Scher, G. Buchanan, W. Gerald, L. M Butler, and W. D Tilley
Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer
Endocr. Relat. Cancer, September 1, 2004; 11(3): 459 - 476.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. E. Taplin and S.-M. Ho
The Endocrinology of Prostate Cancer
J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3467 - 3477.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
E. M. John, G. G. Schwartz, D. M. Dreon, and J. Koo
Vitamin D and Breast Cancer Risk: The NHANES I Epidemiologic Follow-up Study, 1971-1975 to 1992
Cancer Epidemiol. Biomarkers Prev., May 1, 1999; 8(5): 399 - 406.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1984 by The Endocrine Society